EPO decision strengthens UC’s CRISPR patent position in Europe as Editas looks to Cas9 alternatives

A decision at the European Patent Office has confirmed that the CRISPR IP landscape is going to look much different in Europe than it does in the U.S., contributing to the growing complexity of global IP strategies for gene editing developers.

The EPO's board of appeals upheld the revocation of a foundational CRISPR-Cas9 patent from the Broad Institute of MIT and Harvard on Thursday, citing a lack of priority to the earliest priority claims...